文献速递免疫规划卫生政策与健康促进

儿童肺炎球菌结合疫苗接种对侵袭性肺炎球菌疾病的间接效应:系统综述与Meta分析

Indirect effects of childhood pneumococcal conjugate vaccination on invasive pneumococcal disease: a systematic review and meta-analysis.
PubMed 文献 · Lancet Glob Health · 2017-01-01

该系统综述与Meta分析纳入既往综述中70项研究及172项新增研究,覆盖27个高收入国家和7个中等收入国家,采用贝叶斯混合效应模型估计儿童肺炎球菌结合疫苗(PCV)接种后未接种人群侵袭性肺炎球菌疾病的时间性间接效应。结果显示,PCV7覆盖血清型群疾病达到90%降幅的预测平均时间为8.9年(95%可信区间7.8-10.3),PCV13额外6种血清型为9.5年(6.1-16.6);PPV23覆盖血清型群疾病在19-64岁成人(相对风险0.85,95%可信区间0.75-0.95)和65岁及以上人群(0.87,0.84-0.90)年下降速率相似,但PPV23额外11种血清型疾病两组均无变化。

要点

  • PCV7覆盖血清型群疾病达到90%降幅的预测平均时间为8.9年(95%可信区间7.8-10.3)。
  • PCV13额外6种血清型疾病达到90%降幅的预测平均时间为9.5年(95%可信区间6.1-16.6)。
  • PPV23覆盖血清型群疾病年相对风险19-64岁为0.85(0.75-0.95),65岁及以上为0.87(0.84-0.90)。

核心结论

  • 人群儿童PCV规划平均将在十年内为全人群带来实质性保护。
  • 评估老年人群疫苗接种时应考虑这种大规模间接保护。

研究设计与样本

  • 系统综述与Meta分析,检索非随机准实验或观察性研究,报告PCV引入后未接种人群侵袭性肺炎球菌疾病变化。
  • 纳入既往综述中70项研究及172项新增研究,覆盖27个高收入国家和7个中等收入国家。
  • 采用贝叶斯混合效应模型考虑研究间异质性,按血清型和血清群合并侵袭性肺炎球菌疾病变化以估计时间性间接效应。

主要发现

  • PCV7覆盖血清型群疾病达到90%降幅的预测平均时间为8.9年(95%可信区间7.8-10.3)。
  • PCV13额外6种血清型疾病达到90%降幅的预测平均时间为9.5年(95%可信区间6.1-16.6)。
  • PPV23覆盖血清型群疾病年相对风险19-64岁为0.85(95%可信区间0.75-0.95),65岁及以上为0.87(0.84-0.90)。
  • PPV23额外11种血清型疾病在19-64岁和65岁及以上两组均无变化。

关键数值与推荐

  • PCV7覆盖血清型群疾病达到90%降幅的预测平均时间为8.9年(95%可信区间7.8-10.3)。
  • PCV13额外6种血清型疾病达到90%降幅的预测平均时间为9.5年(95%可信区间6.1-16.6)。
  • PPV23覆盖血清型群疾病年相对风险19-64岁为0.85(95%可信区间0.75-0.95),65岁及以上为0.87(0.84-0.90)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The full extent to which childhood pneumococcal conjugate vaccines (PCV) can indirectly reduce illness in unvaccinated populations is not known. We aimed to estimate the magnitude and timing of indirect effects of PCVs on invasive pneumococcal disease. METHODS: In this systematic review and meta-analysis, we searched bibliographic databases for non-randomised quasi-experimental or observational studies reporting invasive pneumococcal disease changes following PCV introduction in unvaccinated populations (studies published Sept 1, 2010, to Jan 6, 2016), updating the previous systematic review of the same topic (studies published Jan 1, 1994, to Sept 30, 2010). Two reviewers extracted summary data by consensus. We used a Bayesian mixed-effects model to account for between-study heterogeneity to estimate temporal indirect effects by pooling of invasive pneumococcal disease changes by serotype and serogroup. FINDINGS: Data were extracted from 70 studies included in the previous review and 172 additional studies, covering 27 high-income and seven middle-income countries. The predicted mean times to attaining a 90% reduction in invasive pneumococcal disease were 8·9 years (95% credible interval [CrI] 7·8-10·3) for grouped serotypes contained in the seven-valent PCV (PCV7), and 9·5 years (6·1-16·6) for the grouped six additional serotypes contained in the 13-valent PCV (PCV13) but not in PCV7. Disease due to grouped serotypes contained in the 23-valent pneumococcal polysaccharide vaccine (PPV23) decreased at similar rates per year in adults aged 19-64 years (relative risk [RR] 0·85, 95% CrI 0·75-0·95) and 65 years and older (0·87, 0·84-0·90). However, we noted no changes in either group in invasive pneumococcal disease caused by the additional 11 serotypes covered by PPV23 but not PCV13. INTERPRETATION: Population childhood PCV programmes will lead, on average, to substantial protection across the whole population within a decade. This large indirect protection should be considered when assessing vaccination of older age groups. FUNDING: Policy Research Programme of the Department of Health, England.

来源:Lancet Glob Health,查看原文。版权归原作者所有。

引用

  1. Shiri T, Datta S, Madan J, et al. Indirect effects of childhood pneumococcal conjugate vaccination on invasive pneumococcal disease: a systematic review and meta-analysis. Lancet Glob Health. 2017. PMID: 27955789. doi:10.1016/S2214-109X(16)30306-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。